Life Edit Therapeutics Appoints Joy A. Cavagnaro to Its Scientific Advisory Board
ncarol.com/10180103

MORRISVILLE, N.C.--(BUSINESS WIRE)--Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation genome editing technologies and therapeutics, today announced the appointment of Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, to its Scientific Advisory Board (SAB). Dr. Cavagnaro is an internationally recognized expert in science-based regulatory strategies and translation of research to preclinical and product development, with an emphasis on genetic medicines.

"We are thrilled to welcome Joy to our Scientific Advisory Board as we rapidly advance our gene editing platform to harness the vast potential of our novel nucleases and base editors as therapeutics," said Mitchell Finer, Ph.D., Chief Executive Officer, Life Edit Therapeutics and President, R&D, ElevateBio. "Joy's expertise in drug discovery and development will complement our esteemed Scientific Advisory Board slate, and collectively our advisors will continue to help Life Edit and our partners further therapeutic programs to address the tremendous unmet needs of genetically-defined diseases."

Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, has more than 40 years of experience in the biotechnology industry and is the President and Founder of Access BIO, where she consults globally on science-based preclinical development strategies. She served at the United States Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) and was appointed to Senior Biomedical Research Service. Dr. Cavagnaro was also the past Chair of the Regulatory Affairs Professional Society (RAPS), President of the National Capital Area Chapter of the Society of Toxicology (SOT), and recipient of the Society's 2019 Arnold J. Lehman Award. Later this year, the American College of Toxicology is expected to recognize Dr. Cavagnaro with the Distinguished Scientist Award in Toxicology. In addition, Dr. Cavagnaro has co-authored numerous white papers, articles, and book chapters related to various aspects of preclinical safety assessment. She received her Ph.D. in Biochemistry from the University of North Carolina at Chapel Hill, followed by post-graduate work at Duke University and Boston University Medical Centers.

More on ncarol.com

• Leimert Park Announces Weeklong Kwanzaa Festival & Kwanzaa Parade Celebrating Black History, Culture, and Community
• Renowned Alternative Medicine Specialist Dr. Sebi and His African Bio Mineral Balance Therapy Are the Focus of New Book
• Psychiatric Drug Damage Ignored for Decades; CCHR Demands Federal Action
• Why Millions Are Losing Sexual Sensation, And Why It's Not Age, Hormones, or Desire
• Justin Jeansonne An Emerging Country Singer-Songwriter Music Fans Have Been Waiting For…a True Maverick

"Life Edit holds one of the largest and most diverse arrays of novel RNA-guided nucleases and base editors that offers flexible editing and unprecedented access to the genome," said Joy Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS. "This powerful technology platform unlocks enormous potential for the development of novel therapeutics, and I look forward to working with the company as they continue to advance their gene editing platform and own internal pipeline of in vivo gene therapies for patients in need."

About Life Edit Therapeutics Inc.

Life Edit Therapeutics, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies. For more information visit lifeeditinc.com or on LinkedIn or Twitter.

More on ncarol.com

• Russellville Huntington Learning Center Expands Access to Literacy Support; Approved Provider Under Arkansas Department of Education
• UK Financial Ltd Launches U.S. Operations Following Delaware Approval
• Pinealage: the app that turns strangers into meditation companions — in crowdfunding phase
• "Micro-Studio": Why San Diegans are Swapping Crowded Gyms for Private, One-on-One Training at Sweat Society
• Beycome Closes $2.5M Seed Round Led by InsurTech Fund

Contacts

Investor Contact:
Catherine Hu
chu@elevate.bio

Life Edit Media Contact:
Courtney Heath
courtney@scientpr.com

---

Show All News | Report Violation